Swiss National Bank Aligos Therapeutics, Inc. Transaction History

Swiss National Bank

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$1.04 - $2.14 $58,448 - $120,268	-56,200 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$14.57 - $17.72 $329,282 - $400,472	22,600 Added 67.26%	56,200 $872,000
Q2 2021 Aug 06, 2021	BUY	$20.3 - $33.6 $682,080 - $1.13 Million	33,600 New	33,600 $685,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.